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OBJECTIVES The aim of this study was to determine the accuracy of the contrast “bolus only” T1 mapping
cardiac magnetic resonance (CMR) technique for measuring myocardial extracellular volume fraction (ECV).
B A C KG ROUND Myocardial ECV can be measured with T1 mapping before and after contrast
agent if the contrast agent distribution between blood/myocardium is at equilibrium. Equilibrium
distribution can be achieved with a primed contrast infusion (equilibrium contrast-CMR [EQ-CMR]) or
might be approximated by the dynamic equilibration achieved by delayed post-bolus measurement.
This bolus only approach is highly attractive, but currently limited data support its use. We compared the
bolus only technique with 2 independent standards: collagen volume fraction (CVF) from myocardial
biopsy in aortic stenosis (AS); and the infusion technique in 5 representative conditions.
METHOD S One hundred forty-seven subjects were studied: healthy volunteers (n  50); hypertro-
phic cardiomyopathy (n  25); severe AS (n  22); amyloid (n  20); and chronic myocardial infarction
(n  30). Bolus only (at 15 min) and infusion ECV measurements were performed and compared. In 18
subjects with severe AS the results were compared with histological CVF.
R E S U L T S The ECV by both techniques correlated with histological CVF (n  18, r2  0.69, p  0.01 vs.
r2  0.71, p  0.01, p  0.42 for comparison). Across health and disease, there was strong correlation
between the techniques (r2 0.97). However, in diseases of high ECV (amyloid, hypertrophic cardiomyopathy
late gadolinium enhancement, and infarction), Bland-Altman analysis indicates the bolus only technique has
a consistent and increasing offset, giving a higher value for ECVs above 0.4 (mean difference  limit of
agreement for ECV 0.4  0.004  0.037 vs. ECV 0.4  0.040  0.075, p  0.001).
CONC L U S I O N S Bolus only, T1 mapping-derived ECV measurement is sufﬁcient for ECV measure-
ment across a range of cardiac diseases, and this approach is histologically validated in AS. However,
when ECV is 0.4, the bolus only technique consistently measures ECV higher compared with
infusion. (J Am Coll Cardiol Img 2013;6:955–62) © 2013 by the American College of Cardiology
Foundation
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956xpansion of the myocardial extracellular vol-
ume is ubiquitous in cardiac disease, whether
as focal scar, diffuse fibrosis, through infil-
tration in amyloidosis, or edema (1). Extra-
cellular volume expansion might represent a key
intermediate phenotype preceding cardiac morbid-
ity and mortality. Recent developments in T1
mapping by cardiac magnetic resonance (CMR)
have permitted its noninvasive quantification. This
new biological parameter has the potential to pro-
vide new mechanistic insights into health and disease
states (2,3) and might have the ability to detect early
disease, guide therapy, and/or predict outcomes (4).
T1 mapping measures myocardial longitudinal
magnetic relaxation, and this can be performed
before and after a standard gadolinium-based con-
trast agent. The contrast agent distributes between
cells embedded in the interstitium be-
tween cells (extracellular space) and blood
plasma such that the relative pre- and
post-contrast signal changes measure the
myocardial extracellular volume fraction
(ECV) (Fig. 1). However, this assumes
that a steady-state equilibrium of gadolin-
ium contrast agent exists between blood
and myocardium. This can be established
by the administration of a primed slow
intravenous contrast infusion—a tech-
nique known as equilibrium contrast car-
diac magnetic resonance (EQ-CMR)
(5)—but it is time consuming and adds
clinical complexity. One alternative is that
at sufficient time after a single contrast
bolus, a dynamic equilibrium might exist
(6,7)—principally because contrast flux
between tissue compartments is faster
than renal excretion—allowing the equiv-
alent ECV measurement. This clinically straight-
forward approach is highly attractive. However,
concerns about the “bolus only” approach have been
raised (8), and although the technique provides
short-term prognostic information (4), it is not
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We hypothesized that the bolus only technique
would be good enough to measure ECV across a
range of cardiac diseases. To achieve this we
compared our results with 2 independent tech-
niques: firstly, with histology, specifically colla-
gen volume fraction (CVF) (%) in severe aortic
stenosis (AS); and secondly, the infusion tech-
nique, EQ-CMR.
M E T H O D S
Bolus only and infusion ECV measurements were
performed and compared with histological CVF in
18 subjects with severe AS and in a population of
147 subjects with a range of different diseases. In
conditions with late gadolinium enhancement
(LGE) where the ECV is high, these areas were
considered separately.
Patients with atrial fibrillation or a contra-
indication to contrast CMR examination were ex-
cluded from the study. The research received ap-
proval from the local research ethics committee, and
all participants provided written informed consent.
The study population consisted of:
1. Normal healthy subjects (n  50, median age
48 [range 24 to 88 years], 51% male) were
recruited through advertising within the hospi-
tal, university, and general practitioner surger-
ies. All normal subjects had no history or
symptoms of cardiovascular disease or diabetes.
Four subjects had been prescribed statin therapy
for hypercholesterolemia (primary cardiovascu-
lar prevention), but no other normal healthy
subject was using any cardiovascular medica-
tion. All subjects had a normal blood pressure
(defined as 140/90 mm Hg), 12-lead electro-
cardiogram, and clinical CMR scan.
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9572. Hypertrophic cardiomyopathy (HCM) patients
(n  25, median age 54 years [range 21 to 75
years], 76% male). All patients met previously
described diagnostic criteria (9). Eighty percent
of patients had an asymmetrical septal hyper-
trophy pattern with the remainder apical pre-
dominant hypertrophy. The mean maximal wall
thickness (from CMR steady-state free preces-
sion short-axis assessment) was 20  4 mm.
Patients were found to have LGE in a variety of
locations, such as at the right ventricular inser-
tion points or the left ventricular apex. LGE
was absent in 4 patients. In 10 patients LGE
was present on pre- and post-contrast T1 maps,
allowing ECV measurement in both HCM
LGE zones and HCM remote zones.
. Severe AS patients (n  22, median age 72
years [range 46 to 84 years], 73% male). All
patients had undergone clinical evaluation and
echocardiography for diagnosis and were listed
for surgical aortic valve replacement.
. Cardiac AL amyloidosis patients (n  20,
median age 62 [range 41 to 76 years], 75%
male). All patients had disease proven by
noncardiac biopsy. Cardiac involvement was
ascertained through echocardiography, sup-
ported by a Mayo clinic classification score of
2 or 3 (10).
. Chronic myocardial infarction patients (n  30,
median age 61 years [range 37 to 75 years], 87%
male). Studies were performed at not 6 months
after an acute ST-segment elevation myocardial
infarction with complete culprit artery occlu-
Figure 1. Calculation of ECV From Pre- and Post-Contrast T1 Ma
The extracellular volume fraction (ECV) was calculated with regions
tion: myocardial ECV  (1  hematocrit)  (R1myocardium/R1bloo
bolus; and 1 at equilibrium. In the future, pixel-by-pixel ECV maps w
chronic inferior infarct was high at 0.82; remote myocardium was 0
is highlighted (small black arrows), with an intermediate ECV of 0.6
contrast administration. The T1 values are given in milliseconds.sion—Thrombolysis In Myocardial Infarctionflow grade 0 (culprit lesions: 11 left anterior
descending artery; 11 right coronary; and 8
circumflex artery). The infarct zone was identi-
fied by routine LGE imaging. Remote myocar-
dium was defined as nonenhancing myocar-
dium outside of the infarct zone.
CMR protocol. The EQ-CMR primed infusion
echnique uses the contrast agent Gadoterate me-
lumine, (gadolinium-DOTA, marketed as Dota-
em, Guerbet S.A., Paris, France) at a dose of 0.1
mol/kg for the bolus and up to an additional 0.1
mol/kg for the infusion, started after a 15-min delay
t 0.0011 mmol/kg/min for a minimum of 30 min (5).
his meant T1 measurements could be made pre-
ontrast agent, at 15 min (dynamic equilibrium time)
ost-contrast agent bolus and at infusion, for 2 ECV
alculations. The scanner used was a conventional
ardiac-enabled magnetic resonance imaging scanner
1.5-T Avanto, Siemens Medical Solutions, Ehrlan-
en, Germany). The T1 mapping sequence employed
as shortened look locker inversion recovery
ShMOLLI). The ShMOLLI T1 mapping was ap-
lied as previously described (11), allowing for stan-
ard cardiac planning adjustments. A complete set of
equence parameters are available online (12).
Analysis. The ShMOLLI sequence T1 maps were
generated with a previously published algorithm
(11). A single region of interest (ROI) was then
drawn for each of the 4 required parameters: myo-
cardial T1 estimates and blood T1 estimates before
and after gadolinium contrast administration. Myo-
cardial T1 was measured in the basal to mid septum
nterest drawn pre- (A) and post-contrast (B) agent with the equa-
here R1  1/T1. Two post-contrast maps exist: 1 at 15 min post-
e constructed automatically online (C) (19). Here, the ECV of this
(infusion result). Infarction of part of the inferior papillary muscle
he large white arrows indicate the change in T1 values followingps
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958avoiding areas of LGE, except in amyloid (where
the ROI was drawn irrespective of the ill-defined
presence/absence of LGE), HCM, and myocardial
infarction (where ROIs were drawn around the
LGE zone itself, and the remote nonenhancing
zone in the short axis) (Fig. 1). Blood T1 was
assessed in the LV cavity blood pool in all subjects,
avoiding the papillary muscles. An ROI in the
septum was chosen, because this corresponds with
the site of previous histological validation (5) and
the site of biopsy in this study.
All analyses were performed blinded to the tech-
nique of ECV measurement. A hematocrit was
taken in all subjects immediately before each CMR
study. The ECV was calculated with each method
as: myocardial ECV  (1hematocrit) 
R1myocardium/ R1blood), where R1  1/T1.
Histological validation. Histological sampling and
analysis was performed in 21 patients with severe
AS listed for surgical aortic valve replacement as
previously described (5). In summary, an intra-
operative deep myocardial biopsy (Tru-Cut type
biopsy needle) was taken from the basal LV septum,
stained with picrosirius red, and photographed at
high-power magnification (200) (Fig. 2). The
CVF (%) was automatically quantified over an
average of 12 high-power fields with a purpose-
written macro in ImageJ (13). All samples were
analyzed (A.S.F.) blinded to the CMR findings and
ECV values. One biopsy specimen was excluded
from analysis in accordance with pre-specified ex-
clusion criteria: 1) extremes of patchy fibrosis (n 
1); and 2) presence of LGE at the site of the biopsy
Figure 2. Histology of an Intra-Myocardial Biopsy Sample in 3 P
Picrosirius red stains collagen (ﬁbrosis) red/pink, and counter stains
automated subtraction of these 2 color stains, which also threshold(n  0). In addition, 2 samples were further txcluded, because they were deemed to be superfi-
ial and included mainly endocardial tissue. One
atient did not undergo sampling, because more than
months had elapsed between the CMR study and
he operative procedure. These 4 patients excluded
rom histological correlation were included in the
omparison of bolus technique with EQ-CMR.
Statistical analysis. All data were normal and expressed
s mean  SD. Correlation between continuous vari-
ables was assessed with Pearson’s test. Comparison of the
strength of correlations was performed as described by
Steiger (14), with a freely available online computer
program (15). The differences between the 2 ECV
techniques and the relationship to the mean were com-
pared with Bland Altman plots, with limits of agreement
quoted as 1.96 SD. Comparison of differences was
ssessed with T tests: unpaired for the means of ECV
bove and below 0.4; and paired for the comparison of
ifferences in means between bolus only and infusion
echniques. Analysis was performed with SPSS version
1 (SPSS, Chicago, Illinois). A statistical significance
evel of 0.05 was used.
R E S U L T S
Histological validation. All biopsies were uneventful.
The mean histological CVF of the 18 biopsies was
17  8% (range 5% to 40%). The ECV by both
techniques correlated well with histological CVF
(r2  0.69, p  0.01 vs. r2  0.71, p  0.01, p 
.42 for comparison) (Fig. 3) and did not differ
tatistically. In keeping with previously published
istological correlation (16), we also found correla-
nts With Severe Aortic Stenosis
ocytes yellow (A). Collagen volume fraction (%) was calculated by
t slicing artifact (seen in B) leaving collagen alone (C).atie
myion with post-contrast T1 values and CVF (bolus
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959only r2 0.21, p 0.04, and infusion r2 0.26, p
0.03), but these were statistically inferior to the ECV
correlation by either technique.
ECV comparison. Across health and disease, there
was strong correlation between ECV as measured
by bolus and infusion techniques (r2  0.97)
Fig. 4). More importantly, in high ECV diseases
amyloid, the late enhancing myocardium in HCM,
nd the infarct zone of myocardial infarction), there
as a consistent and increasing offset on Bland-
ltman analysis (r  0.56, p  0.001), with the
olus technique measuring higher ECV than the
nfusion technique (Fig. 4). An iterative analysis of
ifference showed that, as ECV increased (at 0.05
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Figure 4. Correlation and Bland-Altman Analysis of Comparison
Across Health and Disease
There is an offset toward higher extracellular volume fraction (ECV)
increasing ECV (amyloid, hypertrophic cardiomyopathy [HCM] late g
lines denote the line of identity in the scatterplot and the mean  1.96ntervals) above 0.4, a natural cutpoint was observed
etween the high ECV diseases (amyloid, LGE in
CM, and infarction) and all other conditions
mean difference  limit of agreement for ECV
0.40.004 0.037 vs. ECV0.4 0.040
.075, p  0.001; and across the cohort as a whole
.015  0.061). Mean T1 values pre- and post-
ontrast agent with the bolus only and infusion
echniques are given in Table 1.
D I S C U S S I O N
This is the first study to validate the bolus only
technique against histology. The correlation with
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960CVF was similar to that with the infusion tech-
nique (0.69 vs. 0.71) and did not differ statistically.
When compared with infusion-derived ECV (EQ-
CMR), the bolus only approach seems to be equiv-
alent provided that the disease under study has an
ECV below 0.4. Above this (amyloid, LGE areas of
HCM and chronic myocardial infarction) the bolus
only approach consistently and increasingly pro-
vides a higher ECV. The clinical significance of this
is yet to be explored.
These findings are important, because an ECV
measurement with a bolus only technique is ex-
tremely easy to incorporate into routine clinical
practice—a single breath-hold, here of approxi-
mately 8 s, before and after the contrast agent
administration is all that is required (a total of 6
breath-holds for a 16-segment [“whole-heart”] ap-
proach). The approach might also be generalizable
to other organs (17) and computed tomography
with iodinated contrast agents (18). Given the
potential importance of ECV as a biomarker rep-
resenting interstitial expansion, this result goes
some way to justifying clinical use. In scenarios
where highly accurate ECV measurement is para-
mount (serial follow-up or research setting), a
tailored technique could be employed: for example,
with the advent of online, real-time, motion-
corrected, and co-registration ECV map generation
(shown in Fig. 1) (19,20), the ECV could realisti-
cally be measured at 15 min, and if found to be over
0.4, an infusion could be commenced, and the ECV
could be re-measured with EQ-CMR.
There is now a family of CMR techniques that
use T1 mapping (1). Native or pre-/non-contrast
T1 mapping techniques measure a composite signal
ues Pre- and Post-Contrast Agent With Bolus Only and Infusion T
Normal Subjects
(n  50)
HCM Remote Zone
(n  25)
Severe A
(n  22
1,530 1,519 1,558
only (at 15 min) 496 501 508
n 512 506 465
rast
n
16* 5 43†
968 997 997
only (at 15 min) 600 589 603
n 613 592 575
rast
n
13† 3 28†
*p  0.05; †p  0.01.
 hypertrophic cardiomyopathy; LGE  late gadolinium enhancement.from both myocytes and interstitium but can detect lT1 elevation in disease (fibrosis [21], infarction
[22], and amyloid [23]). A single post-contrast T1
measurement has been used to measure change in
myocardial signal (16,24), but this approach has
been criticized for its lack of correction for con-
founding variables (4). Our data support this, sug-
gesting a significantly lower r2 (0.21 vs. 0.71 with
infusion) when post-contrast T1 values are corre-
lated with CVF. Three techniques advance on this
susceptibility to confounders (by a single post-
contrast T1 assessment), by measuring the ratio of
the blood and myocardial signal change post-
contrast agent with correction for hematocrit to
derive myocardial ECV. These remove kinetics
effect in different ways, leaving signal change de-
pendent only on contrast volume of distribution:
1) the logistic and time demanding primed infusion
technique (EQ-CMR) (5); 2) a multiple measure-
ment technique to derive the slope of the blood/
myocardial contrast dynamics (25); and 3) the bolus
only technique, which assumes a dynamic equilib-
rium occurs with sufficient delay post-bolus, be-
cause blood/myocardial exchange rate constants are
much faster than other effects that influence blood
gadolinium concentration (such as renal excretion).
This dynamic or “pseudo-equilibrium” technique
was explored here: its simplicity gives it maximum
potential clinical utility. Earlier work in healthy
volunteers or patients with modest ECV increases
has demonstrated either little drift in ECV with time
post-bolus (0.6%) (6) or up to 10% over 40 min (8).
urther work is needed to clarify this. It might be
hat such a time dependency is unimportant in
any clinical scenarios. For infarction, however,
ontrast equilibration does not seem to be estab-
niques
Amyloid
(n  20)
HCM LGE Zone
(n  10)
Infarct Zone
(n  30)
Remote Infarct Zone
(n  30)
1,597 1,498 1,532 1,532
590 498 513 513
525 477 447 447
65† 21* 66† 66†
1,137 1,058 1,026 947
539 463 411 601
509 460 381 560
30† 3 30† 41†Table 1. Mean T1 Val ech
S
)
Blood
Pre-contrast
Post-contrast bolus
Post-contrast infusio
Difference post-cont
bolus only infusio
Myocardium
Pre-contrast
Post-contrast bolus
Post-contrast infusio
Difference post-cont
bolus only infusio
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961microvascular obstruction. In chronic infarction,
there is evidence that equilibration can be reached
after 20 min (with a higher dose of contrast agent:
0.2 mmol/kg) (26,27).
Currently, disease-orientated T1 mapping re-
search is fast-developing, but to date, little technical
validation has been presented of the bolus only
approach, either in disease—particularly those with
high ECV values and enhancing myocardium—or
with histological validation with single breath-hold
T1 mapping. Here, we emphasize a difference in
measuring high ECV diseases.
Study limitations. We do not yet know which pre-
ise experimental details are important for bolus
nly T1 mapping. Here, a single contrast bolus (not
plit, as might be used in perfusion protocols) at 3
l/s of a single contrast agent Dotarem (Gadoter-
te meglumine) at 0.1 mmol/kg with post-contrast
1 map at 15 min was performed. Bolus delivery
ate, dose, contrast agent, and timing of post-
ontrast imaging might have modifying effects and
ust be investigated systematically. It might be that
n diseases with ECV 0.4 simply waiting longer
r giving a larger dose might reduce this difference.
urthermore, the data here do not necessarily sup-
ort either approach for serial measurement, for
xample, as a surrogate endpoint in a clinical trial.
n this situation, where other major changes might
e occurring in body composition or hematocrit ordiovascular magnetic resonance for et al. Classificationnfluence, systematically, the residual pharmacoki-
etic effects, the infusion approach is theoretically
ess confounded, but this is unproven. The key
arameter for clinical trials and detecting differ-
nces will be the reproducibility of the respective
easures. Lastly, this study provided biopsy data in
nly 1 disease, and we used only 1 T1 mapping
equence, ShMOLLI. Despite these limitations,
hese data advance the field of ECV measurement
nd provide substantial justification for the simpli-
cation of ECV methodology in this implementa-
ion of the bolus only technique. Further technical
evelopment work will be required before a com-
rehensive model of bolus only ECV measurement
s available, accounting for all potentially relevant
arameters.
C O N C L U S I O N S
A bolus only, T1 mapping-derived ECV measure-
ment is sufficient for ECV measurement across a
range of cardiac diseases, and this approach is now
histologically validated in AS. However, when
ECV is 0.4, the bolus only technique consistently
measures ECV higher, compared with infusion.
Reprint requests and correspondence: Dr. James C. Moon,
he Heart Hospital, 16–18 Westmoreland Street, Lon-
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